New hope for fighting back against aggressive brain cancer
NCT ID NCT04559230
Summary
This study is testing a new drug called sacituzumab govitecan for adults whose aggressive brain cancer (glioblastoma) has returned after initial treatment. The drug is designed to target cancer cells that have high levels of a specific protein. Researchers will give the drug to all participants and compare how long they live to historical data from patients treated with an older chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Texas Oncology Austin
RECRUITINGAustin, Texas, 78705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.